Clinical trial · Observational
Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits
NCT01937286CI-TRIAL-00012038completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Within community with high incidence of HCC, stretching the limits could be justified based on tumor characters and its biological behavior
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrence of HCC After LDLT | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Recurrence of Hepatocellular carcinoma after LDLT
- timeFrame
- at least 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 62 Years
Show eligibility criteria text
Inclusion Criteria: * Egyptien Patients with HCC * Patients within Milan Criteria * Patients beyond Milan criteria are selected on a case by case basis until 2005. From 2005 , patients beyond Milan criteria are subjected to down staging protocol and then reassessed (pre transplantation local ablative therapy either with RFA or TACE according to the size and the site of the lesion and we wait for 12 weeks after ablation ,only those with well ablated lesions, decreased AFP and no denovo lesions were transplanted). Exclusion Criteria: * • Evidence of macro vascular invasion by CT portography and/or US duplex. * Metastatic HCC * General contraindications for LT (ongoing sepsis, other major co morbidities,…). * Early postoperative mortality (first1 month). * Post transplant mortality during the period of follow up due to any cause other than recurrent HCC (e.g. sepsis, rejection, cardiological or cerebrovascular complications…)
References
Publications (0)
Data not yet available
No reference posted for this study.